OncoResponse Reports P-I Study Results of OR502 for the Treatment of Advanced Cancer
Shots:
- The P-I study assesses the safety, tolerability & anti-tumor activity of OR502 alone and with cemiplimab (anti-PD-1) to treat advanced solid tumors, with part A determining MTD & part B finding the RP2D. Biomarker analysis will be carried out throughout the trial
- Trial demonstrated effectiveness as monotx. with 2 PR, 9 SD (N=17) and DCR of 65%. OR502 will be advanced into the next phases consisting of two mini-cohorts, cutaneous melanoma & NSCLC
- OR502 is a humanized antibody that works by blocking LILRB2's interaction with HLA-G on tumor cells to prevent TAM inhibition and boost T cell tumor-killing, enhancing CPI response. Elevated LILRB2 correlates with poor patient survival
Ref: OncoResponse | Image: OncoResponse
Related News:- Abbott Commences New Clinical Trial to Enhance Patient Outcomes in Advanced Heart Failure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
